Biome Launches Human Clinical Trial on BMB18
Filed with ASX · · 5 pages · English
Watch Biome Australia's latest callBiome Australia (ASX:BIO) Q1 2026 Earnings Call · Replay · Oct 22, 2025Read the transcript of Biome Australia (ASX:BIO) Q1 2026 Earnings Call● Ethics approval submitted and study registered with the ANZCTR for Biome’s first human clinical trial on proprietary probiotic strain Lactobacillus plantarum BMB18 ● Trial planned to commence in February 2026 in partnership with La Trobe University ● Randomised, double-blind, placebo-controlled trial recruiting 240 participants across two active dosage levels and placebo, providing robust data f
Earlier from Biome Australia
- Q1 FY26 Revenue Guidance
- Biome Secures New Zealand Pharmacy Deal
- Biome Secures Distribution with Mecca and GoVita
- Financial Year 2025 Preliminary Results
- Preliminary Final Report
Later from Biome Australia
- Trading Update
- Quarterly Activities & Cashflow Report
- Biome secures distribution with Fullscript Canada
- Ethics Approval Granted for BMB18 Human Clinical Trial
- Appendix 4D & Half Yearly Report
Follow Biome Australia into a list and get an email when it puts out news.
Follow Biome Australia